Holen Sie sich die Stockscreener-App
0.2749
0.29%
-0.0008
Schlusskurs vom Vortag:
$0.2757
Offen:
$0.273
24-Stunden-Volumen:
619.03K
Relative Volume:
0.53
Marktkapitalisierung:
$27.52M
Einnahmen:
$1.27M
Nettoeinkommen (Verlust:
$-7.12M
KGV:
-5.2663
EPS:
-0.0522
Netto-Cashflow:
$-5.28M
1W Leistung:
-2.69%
1M Leistung:
-3.88%
6M Leistung:
-18.21%
1J Leistung:
-8.06%
1-Tages-Spanne:
$0.273
$0.2849
1-Wochen-Bereich:
$0.273
$0.2946
52-Wochen-Spanne:
$0.242
$0.4985
IGC Pharma Inc Stock (IGC) Company Profile
Firmenname
IGC Pharma Inc
Sektor
Branche
Telefon
301-983-0998
Adresse
4336 Montgomery Avenue, Bethesda, MD
Compare IGC vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IGC
IGC Pharma Inc
|
0.2749 | 27.52M | 1.27M | -7.12M | -5.28M | -0.0522 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
IGC Pharma Inc Aktie (IGC) Neueste Nachrichten
IGC Pharma Inc (IGC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
IGC Pharma Inc (IGC) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
IGC Pharma Inc (IGC) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
IGC Pharma Inc (IGC) Institutional Confidence - TradingKey
IGC Pharma Inc (IGC) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
IGC Pharma Inc (IGC) Valuation: PE, PB & Fair Value Analysis - TradingKey
IGC Pharma Inc (IGC) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
IGC Pharma Inc (IGC) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
IGC Pharma Reaches Previously Disclosed 146-Patient Enrollment Target in Phase 2 CALMA Trial, Advancing Toward Topline Analysis - ACCESS Newswire
IGC Reaches Enrollment Milestone in Alzheimer's Dementia Trial - GuruFocus
IGC Pharma (NYSE American: IGC) Alzheimer's Drug Gains Attention After Ascendiant Capital Raises Price Target - openPR.com
IGC Pharma (IGC) Inches Up 1.78% as It Approaches Key ResistanceSwing Entry Signals - newsline.com
Agitation in Alzheimer's Disease Market to Register Immense Growth at a CAGR of 14.9% During the Forecast Period (2026-2036) | DelveInsight - 富途牛牛
Alzheimer's agitation drug study nears final data as IGC enrolls 146 patients - Stock Titan
Ascendiant Capital Markets Raises IGC Pharma Price Target to $5.50, Citing Clinical Progress and 2026 Catalysts - BioSpace
IGC Maintained by Ascendiant Capital -- Price Target Raised to $5.50 - GuruFocus
IGC Pharma Extends and Amends $12 Million Loan Facility - TipRanks
IGC Pharma Extends $12 Million O-Bank Credit Facility; Increases Fee to $60,000 - TradingView
IGC Pharma (NYSE: IGC) extends $12M O-Bank loan facility with higher fee - Stock Titan
IGC Pharma, Inc. Enters Into Amendment To Extend Master Loan And Security Agreement With O-Bank Co., Ltd - marketscreener.com
Listed NanoCaps: PMI, IGC, WTC, WOK, SELX Radar Stocks to Watch Now! - openPR.com
Stocks to Watch: ANY, CMND, PRFX, OLOX, IGC Data Centers, AI, Quantum & Healthcare - FinancialContent
IGC Pharma Adds Mount Sinai Clinical Site as CALMA Trial Advances Toward Completion and Topline Analysis - Black Hills Pioneer
IGC Technical Analysis | Trend, Signals & Chart Patterns | IGC PHARMA INC (NYSEARCA:IGC) - ChartMill
IGC Stock Price, Quote & Chart | IGC PHARMA INC (NYSEARCA:IGC) - ChartMill
IGC Pharma Expands CALMA Trial with New Site at Mount Sinai - GuruFocus
IGC Pharma Adds Mount Sinai as CALMA Trial Nears Readout - ACCESS Newswire
IGC Pharma's (NYSE: IGC) CEO Appears on Bloomberg TV Discussing - openPR.com
IGC Pharma’s (NYSE: IGC) CEO Appears on Bloomberg TV Discussing Alzheimer’s Fast-Acting IGC-AD1 Pharmaceutical Therapeutic – More Stocks Inside - Barchart.com
New to The Street's Show #753 Airs Nationwide on Bloomberg Television Across the U.S., MENA and Latin America Featuring FreeCast (NASDAQ:CAST), Stardust Power (NASDAQ:SDST), Lost Soldier Oil and Gas, Virtuix Holdings (NASDAQ:VTIX), and Medi - Newswire.com
IGC Pharma Holds Steady at $0.29 as Stock Consolidates Near Key LevelsMoney Flow - The Legal Advocate
IGC Q1 2026 Earnings: Narrowing Losses on Lower Expenses as EPS Surprises to the UpsideEarnings Volatility Report - newsline.com
Alzheimer's AI Biotech IGC Pharma, Inc. (NYSE: IGC) Stock in FocusMore Stocks Inside - openPR.com
Alzheimer’s AI Biotech IGC Pharma, Inc. (NYSE: IGC) Stock in Focus – More Stocks Inside - Carroll County Mirror-Democrat
Daily Penny AlertsAlzheimer’s AI Biotech IGC Pharma, Inc. (NYSE: IGC) Stock in Focus – More Stocks Inside - FinancialContent
IGC Pharma (IGC) Hovers Near Support After Modest Gain, Awaiting BreakoutETF NAV Deviation - newsline.com
IGC Q1 2026 Earnings: EPS Surpasses Estimates by 14.16% Amid Revenue ChallengesEarnings Revision Report - The Legal Advocate
IGC Pharma Q1 2026 Earnings: Narrower Loss Beats Estimates; Shares Edge LowerTrading Community - Newser
IGC Q1 2026 Earnings: Narrowing Losses as Cost Discipline Drives EPS BeatEarnings Power Value - newsline.com
IGC Pharma earnings beat, revenue topped estimates By Investing.com - Investing.com Australia
IGC Pharma (IGC) Q1 2026 Earnings: $-0.02 EPS Surges Past $-0.02 EstimatesEstimate Revision Count - Newser
IGC Pharma (IGC) Delivers Q1 2026 Beat — EPS $-0.02 vs $-0.02 ExpectedForward EPS Estimate - Newser
IGC Pharma Reports First Quarter 2026 Financial Results with CALMA Phase 2 in the final stage, with 80% Enrollment - BioSpace
Finanzdaten der IGC Pharma Inc-Aktie (IGC)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.74%
1.44%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):